239 related articles for article (PubMed ID: 22057683)
1. A meta-analysis on the effect of corticosteroid therapy in Kawasaki disease.
Zhu BH; Lv HT; Sun L; Zhang JM; Cao L; Jia HL; Yan WH; Shen YP
Eur J Pediatr; 2012 Mar; 171(3):571-8. PubMed ID: 22057683
[TBL] [Abstract][Full Text] [Related]
2. Effect of initial corticosteroid therapy on coronary artery aneurysm formation in Kawasaki disease: a meta-analysis of 862 children.
Wooditch AC; Aronoff SC
Pediatrics; 2005 Oct; 116(4):989-95. PubMed ID: 16199713
[TBL] [Abstract][Full Text] [Related]
3. Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis.
Chen S; Dong Y; Kiuchi MG; Wang J; Li R; Ling Z; Zhou T; Wang Z; Martinek M; Pürerfellner H; Liu S; Krucoff MW
JAMA Pediatr; 2016 Dec; 170(12):1156-1163. PubMed ID: 27749951
[TBL] [Abstract][Full Text] [Related]
4. Corticosteroids for the treatment of Kawasaki disease in children.
Wardle AJ; Connolly GM; Seager MJ; Tulloh RM
Cochrane Database Syst Rev; 2017 Jan; 1(1):CD011188. PubMed ID: 28129459
[TBL] [Abstract][Full Text] [Related]
5. Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary artery aneurysms (CAA) in Kawasaki disease (KD): the KD CAA prevention (KD-CAAP) trial protocol.
Eleftheriou D; Moraes YC; Purvis C; Pursell M; Morillas MM; Kahn R; Mossberg M; Kucera F; Tulloh R; Standing JF; Swallow V; McCormack R; Herberg J; Levin M; Wan M; Klein N; Connon R; Walker AS; Brogan P
Trials; 2023 Jan; 24(1):60. PubMed ID: 36703139
[TBL] [Abstract][Full Text] [Related]
6. Pharmacologic interventions for Kawasaki disease in children: A network meta-analysis of 56 randomized controlled trials.
Lei WT; Chang LS; Zeng BY; Tu YK; Uehara R; Matsuoka YJ; Su KP; Lee PC; Cavalcante JL; Stubbs B; Lin PY; Wu YC; Hsu CW; Chen TY; Chen YW; Yeh PY; Sun CK; Tseng PT; Kao YH
EBioMedicine; 2022 Apr; 78():103946. PubMed ID: 35306339
[TBL] [Abstract][Full Text] [Related]
7. High-Dose Aspirin is Associated with Anemia and Does Not Confer Benefit to Disease Outcomes in Kawasaki Disease.
Kuo HC; Lo MH; Hsieh KS; Guo MM; Huang YH
PLoS One; 2015; 10(12):e0144603. PubMed ID: 26658843
[TBL] [Abstract][Full Text] [Related]
8. The prevention of coronary arterial abnormalities in Kawasaki disease: A meta-analysis of the corticosteroid effectiveness.
Yang TJ; Lin MT; Lu CY; Chen JM; Lee PI; Huang LM; Wu MH; Chang LY
J Microbiol Immunol Infect; 2018 Jun; 51(3):321-331. PubMed ID: 28927685
[TBL] [Abstract][Full Text] [Related]
9. Efficacy between low and high dose aspirin for the initial treatment of Kawasaki disease: Current evidence based on a meta-analysis.
Zheng X; Yue P; Liu L; Tang C; Ma F; Zhang Y; Wang C; Duan H; Zhou K; Hua Y; Wu G; Li Y
PLoS One; 2019; 14(5):e0217274. PubMed ID: 31117119
[TBL] [Abstract][Full Text] [Related]
10. Intravenous immunoglobulin plus corticosteroid to prevent coronary artery abnormalities in Kawasaki disease: a meta-analysis.
Chen S; Dong Y; Yin Y; Krucoff MW
Heart; 2013 Jan; 99(2):76-82. PubMed ID: 22869678
[TBL] [Abstract][Full Text] [Related]
11. Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis.
Friedman KG; Gauvreau K; Baker A; Son MB; Sundel R; Dionne A; Giorgio T; De Ferranti S; Newburger JW
Arch Dis Child; 2021 Mar; 106(3):247-252. PubMed ID: 32943389
[TBL] [Abstract][Full Text] [Related]
12. Management of acute and refractory Kawasaki disease.
Tacke CE; Burgner D; Kuipers IM; Kuijpers TW
Expert Rev Anti Infect Ther; 2012 Oct; 10(10):1203-15. PubMed ID: 23199405
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroid therapy for primary treatment of Kawasaki disease - weight of evidence: a meta-analysis and systematic review of the literature.
Athappan G; Gale S; Ponniah T
Cardiovasc J Afr; 2009; 20(4):233-6. PubMed ID: 19701534
[TBL] [Abstract][Full Text] [Related]
14. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited.
Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM
Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617
[TBL] [Abstract][Full Text] [Related]
15. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease.
Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y
Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370
[TBL] [Abstract][Full Text] [Related]
16. Higher efficacy of infliximab than immunoglobulin on Kawasaki disease, a meta-analysis.
Li X; Tang Y; Ding Y; Chen Y; Hou M; Sun L; Qian G; Qin L; Lv H
Eur J Pharmacol; 2021 May; 899():173985. PubMed ID: 33652059
[TBL] [Abstract][Full Text] [Related]
17. Kawasaki disease: a comprehensive review of treatment options.
Patel RM; Shulman ST
J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
[TBL] [Abstract][Full Text] [Related]
18. Coronary artery lesions and the increasing incidence of Kawasaki disease resistant to initial immunoglobulin.
Kibata T; Suzuki Y; Hasegawa S; Matsushige T; Kusuda T; Hoshide M; Takahashi K; Okada S; Wakiguchi H; Moriwake T; Uchida M; Ohbuchi N; Iwai T; Hasegawa M; Ichihara K; Yashiro M; Makino N; Nakamura Y; Ohga S
Int J Cardiol; 2016 Jul; 214():209-15. PubMed ID: 27070994
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
Miyata K; Kaneko T; Morikawa Y; Sakakibara H; Matsushima T; Misawa M; Takahashi T; Nakazawa M; Tamame T; Tsuchihashi T; Yamashita Y; Obonai T; Chiga M; Hori N; Komiyama O; Yamagishi H; Miura M;
Lancet Child Adolesc Health; 2018 Dec; 2(12):855-862. PubMed ID: 30337183
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in the treatment of Kawasaki disease.
Weng KP; Ou SF; Lin CC; Hsieh KS
J Chin Med Assoc; 2011 Nov; 74(11):481-4. PubMed ID: 22100015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]